Management of Anxiety-Prominent Erectile Dysfunction with Tadalafil

Initial Assessment

Evaluate both organic comorbidities and psychosexual factors in men with anxiety-prominent erectile dysfunction, as both components should be addressed in treatment 2
Screen for cardiovascular risk factors in men with erectile dysfunction, as it can be a risk marker for cardiovascular disease 1
Assess anxiety levels related to sexual situations and performance concerns in men with anxiety-prominent erectile dysfunction 1
Determine if the patient can perform physical activity equivalent to walking 1 mile in 20 minutes or climbing 2 flights of stairs in 20 seconds without symptoms before initiating PDE5 inhibitor therapy 3

Implement lifestyle modifications including smoking cessation, weight loss, increasing physical activity, and reducing alcohol consumption to improve erectile dysfunction symptoms 4, 3
Provide sexual counseling that includes the partner when possible to address anxiety components in men with anxiety-prominent erectile dysfunction 5
Consider referral for psychotherapy or sex therapy as an adjunct to medical treatment, especially for predominantly psychogenic erectile dysfunction 1, 2
Address strategies for reducing anxiety related to sexual situations in men with anxiety-prominent erectile dysfunction 1

Initiate tadalafil as first-line pharmacological therapy for men with anxiety-prominent erectile dysfunction 1
Consider on-demand dosing, starting conservatively and titrating to maximum dose if needed, or daily dosing of 2.5-5 mg for men who prefer spontaneous sexual activity 3, 5
Provide clear instructions to maximize efficacy of tadalafil therapy 1
Monitor periodically for efficacy, side effects, and any significant changes in health status during tadalafil therapy 4
Define an adequate trial as at least 5 separate occasions at the maximum dose before determining ineffectiveness of tadalafil therapy 3

Integrate strategies for incorporating erectile dysfunction treatment into the sexual relationship to address anxiety components 1
For patients with persistent anxiety despite PDE5 inhibitor therapy, intensify psychological support 2

PDE5 inhibitors are contraindicated in patients taking oral nitrates due to risk of dangerous blood pressure decrease 4, 3
If tadalafil is ineffective after adequate trial, consider trying another PDE5 inhibitor before moving to second-line therapies 3
For patients with persistent sexual dysfunction despite PDE5 inhibitor therapy, consider referral to a urologist for second-line interventions 3

Not providing adequate instructions on medication use may reduce efficacy of tadalafil therapy 1
Ignoring partner involvement in treatment can limit success, especially with anxiety-prominent erectile dysfunction 2, 5
Overlooking cardiovascular risk assessment before initiating PDE5 inhibitors can lead to adverse events 3
Stopping treatment prematurely before an adequate trial (at least 5 attempts at maximum dose) may result in inappropriate conclusion of treatment failure 3